Date:_	Oct 19 th , 2021
Vour N	mer Vuanti

Manuscript Title: Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-κB signaling pathways in hypoxic-ischemic brain damage in neonatal mice.

Manuscript number (if known): ATM-21-4958

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>X</u> None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>x</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
	1 U		
9	Participation on a Data	X None	
Ū	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>x</u> None	
	•		
12	Receipt of equipment,	<u>x</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	None.		

Date:_	Oct 19 th , 2021
Your N	ame: Jin-Jia Zhang

Manuscript Title: Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-кВ signaling

<u>pathways in hypoxic-ischemic brain damage in neonatal mice.</u>
Manuscript number (if known): ATM-21-4958

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial X None	planning of the work
ļ	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
Ì			
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>x</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
	1 U		
9	Participation on a Data	X None	
Ū	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>x</u> None	
	•		
12	Receipt of equipment,	<u>x</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	None.		

Date:_	Oct 19th	¹, 2021			
Vour N	lamo: P	Pu-lia Chan			

Manuscript Title: Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-κB signaling pathways in hypoxic-ischemic brain damage in neonatal mice.

Manuscript number (if known): ATM-21-4958

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial X None	planning of the work
-	manuscript (e.g., funding,	<u> </u>	
ļ	provision of study materials,		
ļ	medical writing, article		
	processing charges, etc.) No time limit for this item.		
Ì			
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	x_None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>x</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
	1 U		
9	Participation on a Data	X None	
Ū	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>x</u> None	
	•		
12	Receipt of equipment,	<u>x</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	None.		

Date:_	Oct 19	9 th ,	2021					
Your N	Name:	Lir	ng Chen					

Manuscript Title: Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-κB signaling pathways in hypoxic-ischemic brain damage in neonatal mice.

Manuscript number (if known): ATM-21-4958

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial X None	planning of the work
-	manuscript (e.g., funding,	<u> </u>	
ļ	provision of study materials,		
ļ	medical writing, article		
	processing charges, etc.) No time limit for this item.		
Ì			
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	x_None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>x</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
	1 U		
9	Participation on a Data	X None	
Ū	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>x</u> None	
	•		
12	Receipt of equipment,	<u>x</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	None.		

Date:_	Oct 19 th , 2021			
Vour N	lame: Su Chen			

Manuscript Title: Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-κB signaling pathways in hypoxic-ischemic brain damage in neonatal mice.

Manuscript number (if known): ATM-21-4958

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial X None	pranting of the work
Ì	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
_			
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>x</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
	1 U		
9	Participation on a Data	X None	
Ū	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>x</u> None	
	·		
12	Receipt of equipment,	<u>x</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
None.			

Date:_	Oct 19 th , 2021
Your N	ame: Xiao-Fei Yang

Manuscript Title: Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-кВ signaling

pathways in hypoxic-ischemic brain damage in neonatal mice.

Manuscript number (if known): ATM-21-4958

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial X None	pranting of the work
Ì	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
_			
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>x</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
	1 U		
9	Participation on a Data	X None	
Ū	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>x</u> None	
	•		
12	Receipt of equipment,	<u>x</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
None.			

Date:	Oct 19 ^t	th , 2021				
Your	Name: .	Jia-Wei Min				

Manuscript Title: Genistein mitigates oxidative stress and inflammation by regulating Nrf2/HO-1 and NF-κB signaling pathways in hypoxic-ischemic brain damage in neonatal mice.

Manuscript number (if known): ATM-21-4958

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	<u>X</u> None	
	manuscript (e.g., funding, provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	<u>X</u> None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	<u>X</u> None	
4	Consulting fees	<u>X</u> None	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<u>x</u> None	
	testimony		
7	Support for attending	<u>X</u> None	
	meetings and/or travel		
8	Patents planned, issued or	xNone	
	pending		
	1 U		
9	Participation on a Data	X None	
Ū	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<u>x</u> None	
	•		
12	Receipt of equipment,	<u>x</u> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<u>x</u> None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
None.			